Jyseleca Европска Унија - Исландски - EMA (European Medicines Agency)

jyseleca

gilead sciences ireland uc, galapagos nv - filgotinib maleate - liðagigt, liðagigt - Ónæmisbælandi lyf - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Livostin Nefúði, dreifa 0,5 mg/ml Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

livostin nefúði, dreifa 0,5 mg/ml

mcneil sweden ab - levocabastinum hýdróklóríð - nefúði, dreifa - 0,5 mg/ml

Livostin Augndropar, dreifa 0,5 mg/ml Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

livostin augndropar, dreifa 0,5 mg/ml

mcneil sweden ab - levocabastinum hýdróklóríð - augndropar, dreifa - 0,5 mg/ml